17 stories mentioning AXSMUpdated 9d ago
Every FINWIRES story that references AXSM, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Mark L. Jacobson, Chief Operating Officer, on September 03, 2026, sold 10,000 shares in Axsome Therapeutics (AXSM) for $2,086,500.SEC Filing:https://www.sec.gov/Archives/edgar/data/1579428/000119312526382277/xslF345X05/ownership.xml
Axsome Therapeutics' (AXSM) Auvelity could drive revenue beats for the company, after the therapy's approval and launch in Alzheimer's agitation, RBC said in a Tuesday note.Auvelity's launch in Alzheimer's agitation is meeting or topping Street expectations, RBC said, noting the "statistically robust inflection" in the therapy's new and total prescriptions since the approval in April. The brokerage estimated about 6,300 in new prescriptions in Q2, potentially increasing to around 27,600 in Q3.Meanwhile, total Auvelity prescriptions in Q2 are projected to reach about 9,200, and then grow to around 37,400 in Q3 beyond the baseline trend, according to the note.RBC also said the trends support its estimated $804 million revenue opportunity for Auvelity in 2026, with potential upside of up to $815 million.RBC maintained its outperform rating on Axsome Therapeutics, with a $297 price target.Price: $201.83, Change: $+3.31, Percent Change: +1.67%
Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Eli Lilly (LLY) has agreed to buy Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday. Lilly shares were down 1.6%.Alvotech (ALVO) shares rose past 4% after it said Monday a biologics license application for AVT80 as a proposed interchangeable biosimilar to Entyvio has been accepted for review by the US Food and Drug Administration.Axsome Therapeutics (AXSM) shares added 0.3% after it said Monday that it has dosed the first patient in its phase 3 trial evaluating AXS-05, its experimental drug intended for smoking cessation.
Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $283.25, according to analysts polled by FactSet.Price: $216.19, Change: $+0.42, Percent Change: +0.19%
Axsome Therapeutics' (AXSM) Q2 results showed continued strength from Auvelity, its treatment for major depressive disorder, with the drug's new indication expected to drive revenue growth in H2, RBC Capital Markets said Monday in a report.Auvelity generated $180 million in revenue in the quarter, topping Wall Street's $176 million estimate, "which may help to drive some incremental upside as investors lift their outlook for the drug," the report said.Continued expansion of Auvelity's use in major depressive disorder, including potential benefits from long-term care, should support total revenue of $804 million in 2026, the report said.Auvelity sales may reach $4.3 billion by 2035, with peak sales potentially reaching $5 billion to $6 billion, and the longer-term opportunity is still not fully reflected in Axsome's share price, the report said.RBC lowered its price target on Axsome stock to $297 from $304 and maintained its outperform rating.Price: $220.55, Change: $-0.34, Percent Change: -0.15%
Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and the iShares Biotechnology ETF (IBB) up 0.5%.Sionna Therapeutics (SION) shares fell more than 89% after the company said it will not advance SION-719 as an add-on therapy to standard of care Trikafta in cystic fibrosis patients after a phase 2a proof-of-concept failed to meet its key activity endpoint of sweat chloride reduction.AbCellera Biologics' (ABCL) ABCL635 met the primary efficacy endpoints in the phase 2 portion of a Phase 1/2 study, significantly lowering the frequency and severity of moderate-to-severe hot flashes versus placebo, the company said. AbCellera Biologics stock was up more than 33% pre-bell.Axsome Therapeutics (AXSM) shares were up more than 2% after the company posted a higher Q2 revenue.
The benchmark US stock measures were mostly pointing higher before the opening bell Monday as traders monitor the latest developments in the Middle East and await key inflation data later in the week.The S&P 500 edged up 0.1% and the Nasdaq increased 0.4% in premarket activity, while the Dow Jones Industrial Average slipped 0.2%. The indexes finished Friday trading in the green, with the S&P 500 notching a new closing high.Iranian Foreign Minister Abbas Araghchi said Sunday that Tehran isn't in direct talks with Washington to end their war and reopen the Strait of Hormuz, CNBC reported, citing state media. Araghchi noted that the US will still have to meet Iran's conditions to open the strait, even if a deal is finalized with Oman on the crucial waterway.West Texas Intermediate crude oil inclined 0.9% to $78.85 a barrel before the open, while Brent gained nearly 1% to $84.38.President Donald Trump has signaled that he's prepared to let economic pressure take its toll on Iran instead of mounting another military attack, Axios reported Sunday."We are low-keying it," Trump reportedly said in a phone call, according to Axios. "We are only semi-negotiating with them. We are just watching Iran with its huge inflation and the fact they have no money."With no major economic data scheduled for Monday, traders await the consumer price index for July on Wednesday, followed by wholesale prices and retail sales for the same month on Thursday and Friday, respectively.US Treasury yields were mixed in premarket action, with the two-year rate nudging 0.6 basis points higher to 4.21% while the 10-year rate retreated 0.4 basis points to 4.66%.Last week, official data showed that nonfarm payrolls unexpectedly fell in July, marking the first decline since February. The unemployment rate decreased to 4.1%, the lowest since June 2025 when it stood at the same level.Ferguson Enterprises (FERG), Axsome Therapeutics (AXSM) and monday.com (MNDY) report their latest financial results before the bell, among others. Rocket Lab (RKLB) and Hims & Hers Health (HIMS) post their earnings after the markets close.Shares of Plug Power (PLUG) advanced 5% pre-bell while Palantir Technologies (PLTR) was off 1.4% following a 10% jump at the close of Friday. Super Micro Computer (SMCI) climbed 3.2%.Gold inched up 0.1% to $4,402 per troy ounce, while bitcoin slipped 0.3% to $64,972.
Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $280.53, according to analysts polled by FactSet.
Axsome Therapeutics (AXSM) is seeing continued momentum for its antidepressant Auvelity in major depressive disorder, alongside increasing attention following its FDA approval in Alzheimer's disease agitation, Oppenheimer said in a Wednesday note.The analysts pointed to strong performance in Auvelity's MDD launch and growing investor focus on the Alzheimer's disease agitation indication and its expected uptake trajectory.Oppenheimer also raised peak sales expectations for Auvelity to about $8 billion, driven by broader label expansion, expanded salesforce reach, and growing overlap between MDD and ADA prescribing populations, according to the report.The upcoming catalysts, including the Phase 3 Sunosi readout in binge eating disorder expected in the second half of the year, along with additional pipeline assets and business development opportunities, could further support upside potential for the stock, the report added.Oppenheimer has an outperform rating on the stock with a $280 price target.Price: $233.67, Change: $-0.53, Percent Change: -0.23%
Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.Indivior Pharmaceuticals (INDV) shares were up more than 2% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.Axsome Therapeutics (AXSM) stock was up more than 3% after the company reported higher Q1 revenue while its loss per share increased.ADMA Biologics (ADMA) shares were 0.8% higher after the company said it received US Food and Drug Administration approval for the supplemental biologics license application to expand the label of its Asceniv therapy.
Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%
(Updated to keep price target unchanged).Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $222.90, according to analysts polled by FactSet.
Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $222.90, according to analysts polled by FactSet.Price: $185.08, Change: $+0.08, Percent Change: +0.04%
Axsome Therapeutics (AXSM) has an average rating of Buy and mean price target of $225.25, according to analysts polled by FactSet.Price: $188.87, Change: $+1.53, Percent Change: +0.81%
Ari Maizel, Chief Commercial Officer, on April 22, 2026, sold 7,500 shares in Axsome Therapeutics (AXSM) for $1,368,150.SEC Filing:https://www.sec.gov/Archives/edgar/data/1579428/000119312526174415/xslF345X05/ownership.xml
Axsome Therapeutics' (AXSM) shares are likely facing an "attractive setup" ahead of the US Food and Drug Administration's approval decision of a label expansion of Auvelity into Alzheimer's disease agitation, Oppenheimer said in a note Tuesday.Oppenheimer said it forecasts a 20% upside with a 95% probability versus a 35% downside upon the FDA's decision, reflecting the investment firm's about $2 billion sales estimate, with a priority review for the drug backing its conviction.The investment firm noted Auvelity was originally approved for major depressive disorder in Q3 2022, and was also given breakthrough therapy designation for a potential label expansion into Alzheimer's disease agitation.Oppenheimer said it sees "distinct commercial advantages" for Auvelity, as it may "compete on clean safety, which also justifies formulary positioning and longer-term use" compared with competing Alzheimer's disease agitation drug Rexulti.Meanwhile, Auvelity is also competitively well-positioned compared with candidate drugs in development like Cobenfy, which are "far behind," the note said.Oppenheimer has an outperform rating on Axsome and a $220 price target.Price: $183.26, Change: $-5.43, Percent Change: -2.88%
